Psychiatr. pro Praxi, 2005; 1: 41-43

Teoretické předpoklady a praktické zkušenosti s léčbou amisulpridem

MUDr. Pavel Doubek1, MUDr. Markéta Zemanová2, MUDr. Petr Kozelek1
1 Psychiatrická klinika 1. LF UK a VFN Praha
2 Psychiatrická léčebna, Havlíčkův Brod

Zavedení atypických antipsychotik přineslo podstatné zvýšení účinnosti léčby schizofrenie a současné snížení výskytu vedlejších nežádoucích účinků. Atypická antipsychotika jsou heterogenní lékovou skupinou s rozdílnými mechanismy účinku, účinností, snášenlivostí a profilem nežádoucích účinků. Pro velké množství publikovaných informací o jednotlivých preparátech je někdy problematické vytvořit si jasný obraz o možnostech a výhodách jejich užití v klinické praxi. Proto si část lékařů tvoří názor na základě vlastní nebo sdělené klinické zkušenosti.

V našem sdělení se snažíme ukázat oba možné způsoby utváření názoru na atypické antipsychotikum amisulprid a jeho využití v klinické praxi.

Published: February 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doubek P, Zemanová M, Kozelek P. Teoretické předpoklady a praktické zkušenosti s léčbou amisulpridem. Psychiatr. praxi. 2005;9(1):41-43.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adams CE, Coutinho E, Duggan L, Gilbody S, Leucht S, Wahlbeck K. Cochrane Schizophrenia Group. Cochrane Database Syst Rev. 2003; 4: CDD51334.
    2. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003; 60: 553-564. Go to original source... Go to PubMed...
    3. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J. 2000; 321: 1371-1375. Go to original source... Go to PubMed...
    4. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B: Effectivness of second-generation antipsychoics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001; 158: 518-526. Go to original source... Go to PubMed...
    5. Leucht S, Pitschel-Waltz G, Abraham D, Kissling W. Efficacy and extrapyramidal side effects of the bew antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised controlled trials. Schizophr Res. 1999; 35: 51-68. Go to original source... Go to PubMed...
    6. Leucht S, Pitschel-Waltz G, Engel RR, Kissling W. Amisulpride, an unusual, ,atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry. 2002; 159: 180-190. Go to original source... Go to PubMed...
    7. Leucht S, Wahlbeck K, Hamann J, Kissling W. New antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003; 361: 1581-1589. Go to original source... Go to PubMed...
    8. National Institute for Clinical Excellence. Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal no. 43. London 2002, UK: NICE.
    9. Peuskens J, Möller HJ, Peuch A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacology. 2002; 12: 305-310. Go to original source... Go to PubMed...
    10. Pidrman V, Látalová K. Amisulprid - mýty a fakta. Psy pro Praxi. 2004; 5: 276-280.
    11. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics. Epidemiology and therapeutic implications. CNS Drugs. 2001; 15, 7: 537-551. Go to original source... Go to PubMed...
    12. Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet Q, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor anatagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997; 280: 83-97. Go to PubMed...
    13. Storosum JG, Elferink AJA, van Zweiten BJ, van Strik R, Hoogendijk WJG, Broekmans AW: Amisulpride: is there a treatment for negative symptoms in schizophrenia patients? Schizophr Bull. 2002; 28: 193-201. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.